Joint Associations of Cardiovascular Health and Polygenic Risk with Incident Cardiovascular Disease across the CKM Syndrome Continuum: A Prospective Cohort Study

Background: Prior studies of cardiovascular health (CVH) and genetic susceptibility have not accounted for heterogeneity in underlying cardiometabolic-renal states. Whether ideal CVH protects against cardiovascular disease (CVD) across the cardiovascular-kidney-metabolic (CKM) syndrome continuum, and whether this benefit is modified by CKM stage or genetic susceptibility, remains unknown. Methods: This prospective study included 242,951 UK Biobank participants (aged 37–73) in CKM Stages 0–3, free of CVD at baseline (2006–2010), followed through 2022. CVH was quantified using Life’s Essential 8 (LE8) (poor, <50; intermediate, 50–79; ideal, ≥80). A cardiovascular-specific polygenic risk score (PRS) was categorized into tertiles. The primary outcome was incident composite CVD. Multivariable Cox models estimated hazard ratios (HRs); cumulative incidence functions accounting for competing mortality were compared by Gray’s test. Results: Among 242,951 participants (mean age, 55.7 years; 53.1% women), 39,355 incident CVD events occurred over a median follow-up of 15.2 years. Ideal CVH was associated with 53% lower CVD risk versus poor CVH (HR, 0.47; 95% CI, 0.45–0.49), with the largest reductions for heart failure (HF) (HR, 0.33) and coronary heart disease (CHD) (HR, 0.35). Higher CVH was associated with lower CVD risk across genetic risk strata. No CKM × CVH interaction was detected (P = .335), indicating preserved protection across the disease continuum; a significant CKM × PRS interaction (P = .003) indicated amplified polygenic risk impact in advanced stages. Both CVH- and PRS-based stratification significantly separated cumulative CVD incidence across all CKM stages (all Gray’s test P < .001). Results were robust to inverse probability weighting (IPW), competing risk models, and landmark analyses. Conclusion: Favorable CVH was associated with substantially lower CVD risk across the full CKM continuum without attenuation in advanced disease, whereas polygenic risk consequences were amplified in later CKM stages. These findings support integrating CVH assessment as a complementary axis within CKM risk stratification.

Authors

Institutions

Publication Details

Journal
Global Heart
Published
2026-11-17
DOI
https://doi.org/10.5334/gh.1603
Primary Topic
Cardiovascular Health and Risk Factors
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Joint Associations of Cardiovascular Health and Polygenic Risk with Incident Cardiovascular Disease across the CKM Syndrome Continuum: A Prospective Cohort Study

Sizhuang Huang, Hao Zhang, Mengyue Yu, Haihua Zhang et al.
7 links
Global Heart
Cardiovascular Health and Risk Factors
article

Joint Associations of Cardiovascular Health and Polygenic Risk with Incident Cardiovascular Disease across the CKM Syndrome Continuum: A Prospective Cohort Study

Sizhuang Huang, Hao Zhang, Mengyue Yu, Haihua Zhang, Yanwen Fang, Weixian Yang, Mingyang Li
article en

Abstract

Background: Prior studies of cardiovascular health (CVH) and genetic susceptibility have not accounted for heterogeneity in underlying cardiometabolic-renal states. Whether ideal CVH protects against cardiovascular disease (CVD) across the cardiovascular-kidney-metabolic (CKM) syndrome continuum, and whether this benefit is modified by CKM stage or genetic susceptibility, remains unknown. Methods: This prospective study included 242,951 UK Biobank participants (aged 37–73) in CKM Stages 0–3, free of CVD at baseline (2006–2010), followed through 2022. CVH was quantified using Life’s Essential 8 (LE8) (poor, <50; intermediate, 50–79; ideal, ≥80). A cardiovascular-specific polygenic risk score (PRS) was categorized into tertiles. The primary outcome was incident composite CVD. Multivariable Cox models estimated hazard ratios (HRs); cumulative incidence functions accounting for competing mortality were compared by Gray’s test. Results: Among 242,951 participants (mean age, 55.7 years; 53.1% women), 39,355 incident CVD events occurred over a median follow-up of 15.2 years. Ideal CVH was associated with 53% lower CVD risk versus poor CVH (HR, 0.47; 95% CI, 0.45–0.49), with the largest reductions for heart failure (HF) (HR, 0.33) and coronary heart disease (CHD) (HR, 0.35). Higher CVH was associated with lower CVD risk across genetic risk strata. No CKM × CVH interaction was detected (P = .335), indicating preserved protection across the disease continuum; a significant CKM × PRS interaction (P = .003) indicated amplified polygenic risk impact in advanced stages. Both CVH- and PRS-based stratification significantly separated cumulative CVD incidence across all CKM stages (all Gray’s test P < .001). Results were robust to inverse probability weighting (IPW), competing risk models, and landmark analyses. Conclusion: Favorable CVH was associated with substantially lower CVD risk across the full CKM continuum without attenuation in advanced disease, whereas polygenic risk consequences were amplified in later CKM stages. These findings support integrating CVH assessment as a complementary axis within CKM risk stratification.

Global HeartVol. 21(1)
Chinese Academy of Medical Sciences & Peking Union Medical College (CN), Fu Wai Hospital (CN), State Key Laboratory of Cardiovascular Disease (CN)
Good health and well-being
Cardiovascular Health and Risk Factors
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon